Alloantigen specific deletion of primary human T cells by Fas ligand (CD95L)-transduced monocyte-derived killer-dendritic cells

Immunology

Volumn 133, Issue 1, 2011, Pages 115-122

  Schütz, Christian ^a   Hoves, Sabine ^a,d   Halbritter, Dagmar ^a   Zhang, Huang Ge ^b   Mountz, John D ^c   Fleck, Martin ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b University of Louisville School of Medicine   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

Dendritic cells; Graft versus host disease; T cell; Tolerance

Indexed keywords

ADENOVIRUS VECTOR; ALLOANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; FAS LIGAND; GREEN FLUORESCENT PROTEIN;

ALLOIMMUNITY; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INTERACTION; CELL PROLIFERATION; CELL STIMULATION; COCULTURE; DENDRITIC CELL; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; MONOCYTE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SEPARATION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; ISOANTIGENS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONOCYTES; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 79953323259     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2011.03417.x     Document Type: Article

References (42)

1. Sato K, Fujita S. Dendritic cells: nature and classification. Allergol Int 2007; 56:183-91.
2. Onoe K, Yanagawa Y, Minami K, Iijima N, Iwabuchi K. Th1 or Th2 balance regulated by interaction between dendritic cells and NKT cells. Immunol Res 2007; 38:319-32.
3. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 2002; 20:621-67.
4. Wu L, Liu YJ. Development of dendritic-cell lineages. Immunity 2007; 26:741-50.
5. Lanzavecchia A, Sallusto F. Regulation of T cell immunity by dendritic cells. Cell 2001; 106:263-6.
6. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19:47-64.
7. Jonuleit H, Schmitt E, Steinbrink K, Enk AH. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001; 22:394-400.
8. Cools N, Ponsaerts P, Van Tendeloo VF et al. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol 2007; 82:1365-74.
9. Proietto AI, van Dommelen S, Wu L. The impact of circulating dendritic cells on the development and differentiation of thymocytes. Immunol Cell Biol 2009; 87:39-45.
10. + T-cell cross-tolerance by dendritic cells. Eur J Immunol 2009; 39:2325-30.
11. Ehser S, Chuang JJ, Kleist C, Sandra-Petrescu F, Iancu M, Wang D, Opelz G, Terness P. Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum Immunol 2008; 69:165-73.
12. Chauvin C, Philippeau JM, Hemont C et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res 2008; 68:9433-40.
13. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26.
14. Krueger A, Fas SC, Baumann S, Krammer PH. The role of CD95 in the regulation of peripheral T-cell apoptosis. Immunol Rev 2003; 193:58-69.
15. Schutze S, Tchikov V, Schneider-Brachert W. Regulation of TNFR1 and CD95 signalling by receptor compartmentalization. Nat Rev Mol Cell Biol 2008; 9:655-62.
16. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007; 7:532-42.
17. Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009; 127:145-54.
18. Fas SC, Fritzsching B, Suri-Payer E, Krammer PH. Death receptor signaling and its function in the immune system. Curr Dir Autoimmun 2006; 9:1-17.
19. Min WP, Gorczynski R, Huang XY et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164:161-7.
20. Matsue H, Matsue K, Walters M, Okumura K, Yagita H, Takashima A. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected 'killer' dendritic cells. Nat Med 1999; 5:930-7.
21. Buonocore S, Van Meirvenne S, Demoor FX, Paulart F, Thielemans K, Goldman M, Flamand V. Dendritic cells transduced with viral interleukin 10 or Fas ligand: no evidence for induction of allotolerance in vivo. Transplantation 2002; 73(1 Suppl):S27-30.
22. Kusuhara M, Matsue H. Limitations of CD95 ligand-transduced killer dendritic cells to prevent graft rejections. Exp Dermatol 2005; 14:273-80.
23. Strauss G, Osen W, Knape I, Jacobsen EM, Muller SM, Debatin KM. Membrane-bound CD95 ligand expressed on human antigen-presenting cells prevents alloantigen-specific T cell response without impairment of viral and third-party T cell immunity. Cell Death Differ 2007; 14:480-8.
24. Hoves S, Krause SW, Halbritter D, Zhang HG, Mountz JD, Scholmerich J, Fleck M. Mature but not immature Fas ligand (CD95L)-transduced human monocyte-derived dendritic cells are protected from Fas-mediated apoptosis and can be used as killer APC. J Immunol 2003; 170:5406-13.
25. + T cells by Fas ligand (FasL/CD95L)-expressing killer-dendritic cells. Immunobiology 2004; 208:463-75.
26. Ammon C, Meyer SP, Schwarzfischer L, Krause SW, Andreesen R, Kreutz M. Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells. Immunology 2000; 100:364-9.
27. Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, Schmitt E, Knop J, Enk AH. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997; 27:3135-42.
28. Zhang HG, Liu D, Heike Y et al. Induction of specific T-cell tolerance by adenovirus-transfected, Fas ligand-producing antigen presenting cells. Nat Biotechnol 1998; 16:1045-9.
29. Bilbao G, Zhang H, Contreras JL, Zhou T, Feng M, Saito I, Mountz JD, Curiel DT. Construction of a recombinant adenovirus vector encoding Fas ligand with a CRE/Loxp inducible system. Transplant Proc 1999; 31:792-3.
30. Graham FL, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995; 3:207-20.
31. Gahn B, Siller-Lopez F, Pirooz AD et al. Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma. Int J Cancer 2001; 93:706-13.
32. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 1995; 377:348-51.
33. + T-cell selection, function, and death in the primary immune response in vivo. J Clin Invest 2000; 106:1251-61.
34. Nouri-Shirazi M, Thomson AW. Dendritic cells as promoters of transplant tolerance. Expert Opin Biol Ther 2006; 6:325-39.
35. Bohana-Kashtan O, Civin CI. Fas ligand as a tool for immunosuppression and generation of immune tolerance. Stem Cells 2004; 22:908-24.
36. Suchin EJ, Langmuir PB, Palmer E, Sayegh MH, Wells AD, Turka LA. Quantifying the frequency of alloreactive T cells in vivo: new answers to an old question. J Immunol 2001; 166:973-81.
37. Shimizu T, Takeda S. CD8 T cells from major histocompatibility complex class II-deficient mice respond vigorously to class II molecules in a primary mixed lymphocyte reaction. Eur J Immunol 1997; 27:500-8.
38. Schutz C, Fleck M, Mackensen A, Zoso A, Halbritter D, Schneck JP, Oelke M. Killer artificial antigen-presenting cells: a novel strategy to delete specific T cells. Blood 2008; 111:3546-52.
39. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-61.
40. Kayagaki N, Kawasaki A, Ebata T et al. Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995; 182:1777-83.
41. Talmadge JE. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. Int Immunopharmacol 2003; 3:1121-43.
42. Buonocore S, Paulart F, Le Moine A et al. Dendritic cells overexpressing CD95 (Fas) ligand elicit vigorous allospecific T-cell responses in vivo. Blood 2003; 101:1469-76.